Dopastatin
Also known as: BIM-23268, BIM-23A387, BIM-23A760, chimeric SST-DA agonist
Source Dopastatin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dopastatin (also called BIM-23A760 or similar chimeric analogs) is an experimental chimeric peptide combining somatostatin and dopamine pharmacophores. It was developed to overcome partial resistance to individual somatostatin analogs or dopamine agonists in acromegaly and prolactinoma, leveraging receptor heterodimerization for enhanced suppression of GH and prolactin. Multiple chimeric dopastatins (e.g., BIM-23A387, BIM-23A760) have been studied in preclinical and early clinical settings.
Mechanism of Action
Dopastatin compounds are chimeric molecules that simultaneously activate somatostatin receptors (primarily SSTR2 and SSTR5) and dopamine D2 receptors, thereby providing synergistic inhibition of growth hormone and prolactin secretion beyond what either class of agent achieves alone.
Routes of Administration
Goals & Uses
- Overcoming somatostatin analog resistancePharmacologicalModerate
- Prolactin suppressionEndocrineModerate
- Treatment of neuroendocrine tumorsOncologyLow
- Reduction of growth hormone hypersecretion in acromegalyEndocrineModerate
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to somatostatin analogs or dopamine agonistsAllergy/ImmunologyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- CholelithiasisHepatobiliaryUncommon
- Gastrointestinal disturbances (nausea, diarrhea, abdominal cramping)GastrointestinalCommon
- Orthostatic hypotensionCardiovascularUncommon
- Nausea and vomitingGastrointestinalCommon
- Hypoglycemia or hyperglycemiaMetabolicUncommon
Drug Interactions
- CyclosporineModerate
- Antidiabetic agents (insulin, sulfonylureas)Moderate
- Dopamine antagonists (e.g., haloperidol, metoclopramide)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with Parkinson's disease on dopaminergic therapyNeurologicalRelative
- Elderly patients (>75 years)AgeRelative
Regulatory Status
- European UnionInvestigationalNo EMA approval; clinical investigations conducted in European centers.
- United StatesInvestigationalNo FDA approval; studied under IND/clinical trial frameworks for acromegaly.
- United KingdomInvestigationalNo MHRA approval; research/trial use only.
No regulatory approval in any jurisdiction as of current knowledge cutoff. Investigational use only; studied in Phase I/II clinical trials for acromegaly and neuroendocrine tumors.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dopastatin?
Dopastatin (also called BIM-23A760 or similar chimeric analogs) is an experimental chimeric peptide combining somatostatin and dopamine pharmacophores. It was developed to overcome partial resistance to individual somatostatin analogs or dopamine agonists in acromegaly and prolactinoma, leveraging receptor heterodimerization for enhanced suppression of GH and prolactin. Multiple chimeric dopastatins (e.g., BIM-23A387, BIM-23A760) have been studied in preclinical and early clinical settings.
What is Dopastatin used for?
Dopastatin is educationally associated with: Overcoming somatostatin analog resistance, Prolactin suppression, Treatment of neuroendocrine tumors, Reduction of growth hormone hypersecretion in acromegaly. Educational only — not medical advice.
How is Dopastatin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Dopastatin?
Reported adverse effects include: Injection site reactions, Cholelithiasis, Gastrointestinal disturbances (nausea, diarrhea, abdominal cramping), Orthostatic hypotension, Nausea and vomiting, Hypoglycemia or hyperglycemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dopastatin?
Recorded contraindications: Severe hepatic impairment, Pregnancy, Hypersensitivity to somatostatin analogs or dopamine agonists. Consult a qualified clinician before use.